Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review
Liver transplantation · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes liver transplantation compared with placebo (very low certainty).
1 finding from 1 review
Malignancy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
Colorectal cancer · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether antioxidants changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Short‐term mortality (< 1 year) · people with acute HBV infection
It is very uncertain whether lamivudine changes short‐term mortality (< 1 year) compared with no intervention (very low certainty).
1 finding from 1 review